What does circulating tumor DNA (ctDNA) testing tell me about my Ovarian Cancer

Understanding Circulating Tumor DNA (ctDNA) Testing for Ovarian Cancer

I'm glad you're asking about this—ctDNA testing is an emerging tool that can provide valuable information about your cancer, though it's important to understand both what it can and cannot tell you.

What Is ctDNA?

Circulating tumor DNA (ctDNA) is DNA from your cancer cells that has entered your bloodstream. Think of it as "liquid biopsy"—instead of removing tissue for testing, doctors can detect cancer DNA fragments floating in your blood plasma. This is a non-invasive way to monitor your cancer without needing additional biopsies.

What ctDNA Testing Can Tell You

For Ovarian Cancer Specifically:

According to NCCN Guidelines for Ovarian Cancer, ctDNA (also called liquid biopsy) can be used when tissue-based analysis isn't clinically feasible. Here's what it may reveal:

1. Molecular Alterations That Guide Treatment

ctDNA testing can identify important genetic mutations in your cancer, including:

• BRCA1/2 mutations — These are critical because they determine eligibility for PARP inhibitor maintenance therapy (drugs that work particularly well for BRCA-mutated cancers)
• Homologous recombination deficiency (HRD) status — This indicates how well your cancer can repair DNA damage, which affects treatment options
• Other mutations like BRAF, NTRK, MSI (microsatellite instability), and MMR (mismatch repair) status — These may open doors to targeted therapies

2. Disease Monitoring Over Time

According to research on liquid biopsies, ctDNA can help track:

• Whether your cancer is responding to treatment
• Early signs of disease progression before imaging shows changes
• Changes in your cancer's genetic makeup during treatment

3. Treatment Resistance Patterns

ctDNA testing can reveal how your cancer is evolving and adapting to treatment, which helps your oncologist decide when to switch therapies.

Important Limitations to Understand

ctDNA testing has real constraints you should know about:

1. It's Not a Replacement for Tissue Testing

   • According to NCCN Guidelines, tissue-based testing is still preferred when possible, especially for initial diagnosis
   • ctDNA has appreciable false-negative rates (meaning it can miss mutations that are actually present)
   • Tissue testing remains the gold standard for comprehensive analysis

2. Low Tumor Fraction Issues

   • If you have a small amount of circulating tumor DNA in your blood, the test may not detect it
   • Some assays measure "ctDNA fraction" to help identify when sensitivity might be compromised

3. It Can Detect Non-Cancer DNA

   • Your blood may contain DNA from normal aging processes (called clonal hematopoiesis) that can be mistaken for cancer mutations
   • This is why results need careful interpretation by your oncology team

4. Timing Matters

   • Results can vary depending on when the test is done relative to your treatment
   • A single test provides a snapshot; serial testing (repeated over time) is more informative

When ctDNA Testing Is Most Useful for Ovarian Cancer

Based on NCCN Guidelines, ctDNA testing may be particularly helpful:

• At diagnosis — If tissue samples are difficult to obtain or if you have advanced disease
• During treatment — To monitor response to chemotherapy or targeted therapy
• After treatment — To detect early recurrence before symptoms appear
• At recurrence — To identify new mutations that might respond to different targeted therapies

Questions to Ask Your Oncologist

Since ctDNA testing is still evolving, here are specific questions to discuss with your care team:

1. "Do you recommend ctDNA testing for my specific situation, and why?"
2. "Will this test replace my tissue biopsy results, or complement them?"
3. "How will you use these results to change my treatment plan?"
4. "How often would you repeat this test, and what would trigger a repeat?"
5. "What happens if the ctDNA test is negative—does that mean I'm cancer-free?" (Important: negative ctDNA doesn't guarantee no cancer; it just means none was detected in the blood at that moment)

The Bottom Line

ctDNA testing is a promising tool that can provide real insights into your cancer's genetics and treatment response. However, it works best as part of a complete picture—combined with imaging, physical exams, traditional tumor markers (like CA-125), and tissue analysis when available.

The research shows that combining multiple approaches gives your oncologist the most complete understanding of your cancer and the best chance of selecting the right treatment for you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.